Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might ...

long-acting subcutaneous depot of octreotide under development for the treatment of three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET ...

In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach ...

They will talk about the benefits and the possible side effects. The type of neuroendocrine cancer means whether you have a NET or NEC. There are then different subtypes: There are 3 different types ...

She initially received a long-acting somatostatin analog (octreotide ... had been diagnosed as having metastatic pulmonary neuroendocrine tumor. The patient's medical and family history was ...

NET: Neuroendocrine tumor. Data from [20,94 ... Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years.